Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 52, Issue 1, 2003, Pages

  Yamori, Takao ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Anticancer drug discovery; Bioinformatics; Cancer cell line panel; Chemosensitivity; Gene expression

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACLARUBICIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; COLCHICINE; DACTINOMYCIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOLASTATIN 10; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FJ 5002; GEMCITABINE; GYRASE INHIBITOR; IRINOTECAN; MERCAPTOPURINE; MITOXANTRONE; MS 247; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TELOMERASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; BIOINFORMATICS; CANCER CELL CULTURE; COMPUTER PROGRAM; CONFERENCE PAPER; DRUG RESEARCH; DRUG SCREENING; HUMAN; PRIORITY JOURNAL;

DATABASES, FACTUAL; DATABASES, GENETIC; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0042827269     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Boyd MR (1989) Status of the National Cancer Institute preclinical antitumor drug discovery screen: implications for selection of new agents for clinical trial. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology update, vol 3. Lippincott Williams & Wilkins, Philadelphia, p 1
2. Dan S, Yamori T (2001) Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells. Biochem Biophys Res Commun 280:861
3. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T (2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62:1139
4. Di Francesco AM, Ruggiero A, Riccardi R (2002) Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 59:1914
5. Hashimoto S, Xu Y, Masuda Y, Aiuchi T, Nakajo S, Uehara Y, Shibuya M, Yamori T, Nakaya K (2002) β-Hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res 93:944
6. Hosokawa N, Iinuma H, Takeuchi T, Sato S, Yamori T, Tsuchiya KS, Hori M (2000) Anticancer and some biological activities of thiazinotrienomycin B. J Antibiot (Tokyo) 53:306
7. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrichi M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757
8. Naasani I, Seimiya H, Yamori T, Tsuruo T (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59:4004
9. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088
10. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227
11. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236
12. Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117
13. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343
14. Yamori T, Sato S, Chikazawa H, Kadota T (1997) Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res 88:1205
15. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T (1999) Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 59:4042
16. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN (2002) Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 62:1688